Q4FY24 Quarterly & FY24 Annual Result Announced for Hester Biosciences Ltd.
Pharmaceuticals company Hester Biosciences announced Q4FY24 & FY24 results: Financial Highlights: Hester Biosciences reported an increase in standalone revenue by 20% and consolidated revenue by 18% in Q4FY24 compared to the previous year. The audited financial results for Q4 & FY24 show the company's resilience with a recommendation for a dividend of 6 per equity share of Rs 10 each (60%) for FY24, awaiting shareholder approval. The company has reduced its borrowing by 19% and increased cash generated from operations by 28% during the year. Overall gross profit margin in Q4FY24 increased by 1% compared to Q4FY23, primarily due to the increase in the proportion of vaccines from 60% to 75% in Q4FY24. In Q4FY24, EBITDA increased by 14% in alignment with a growth in sales, resulting in a 19% increase in PAT for the quarter. The total borrowings of the Company has reduced by Rs 307.58 million (19%) during the year. The cash generated from operations has increased by Rs 94.50 million (28%) during the year Animal Healthcare Division: The Animal Healthcare division saw a growth of 89% in Q4FY24, driven by sales of Goat Pox vaccine and vaccines for a government immunisation program. Despite regulatory challenges, the Animal Healthcare division has demonstrated the ability to recover and sustain growth. Poultry Healthcare Division: The Poultry Healthcare division achieved a notable growth of 22% in Q4FY24, with a consistent upward trend throughout the year. Strategic introductions of new products and leveraging market opportunities have been instrumental in the division's sales performance. Petcare Division: In Q4FY24, the Petcare division saw a minor decrease in sales from the previous quarter but reported a notable annual growth of 49%. The Petcare division's focus on building a strong foundation and delivering high-quality products is reflected in its substantial growth. Result PDF10-05-2024